Brain imaging predictors and the international study to predict optimized treatment for depression: Study protocol for a randomized controlled trial

Stuart M. Grieve, Mayuresh S. Korgaonkar, Amit Etkin, Anthony Harris, Stephen H. Koslow, Stephen Wisniewski, Alan F. Schatzberg, Charles Nemeroff, Evian Gordon, Leanne M. Williams

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Approximately 50% of patients with major depressive disorder (MDD) do not respond optimally to antidepressant treatments. Given this is a large proportion of the patient population, pretreatment tests that predict which patients will respond to which types of treatment could save time, money and patient burden. Brain imaging offers a means to identify treatment predictors that are grounded in the neurobiology of the treatment and the pathophysiology of MDD.Methods/Design: The international Study to Predict Optimized Treatment in Depression is a multi-center, parallel model, randomized clinical trial with an embedded imaging sub-study to identify such predictors. We focus on brain circuits implicated in major depressive disorder and its treatment. In the full trial, depressed participants are randomized to receive escitalopram, sertraline or venlafaxine-XR (open-label). They are assessed using standardized multiple clinical, cognitive-emotional behavioral, electroencephalographic and genetic measures at baseline and at eight weeks post-treatment. Overall, 2,016 depressed participants (18 to 65 years old) will enter the study, of whom a target of 10% will be recruited into the brain imaging sub-study (approximately 67 participants in each treatment arm) and 67 controls. The imaging sub-study is conducted at the University of Sydney and at Stanford University. Structural studies include high-resolution three-dimensional T1-weighted, diffusion tensor and T2/Proton Density scans. Functional studies include standardized functional magnetic resonance imaging (MRI) with three cognitive tasks (auditory oddball, a continuous performance task, and Go-NoGo) and two emotion tasks (unmasked conscious and masked non-conscious emotion processing tasks). After eight weeks of treatment, the functional MRI is repeated with the above tasks. We will establish the methods in the first 30 patients. Then we will identify predictors in the first half (n = 102), test the findings in the second half, and then extend the analyses to the total sample.Trial registration: International Study to Predict Optimized Treatment - in Depression (iSPOT-D). ClinicalTrials.gov, NCT00693849.

Original languageEnglish
Article number224
JournalTrials
Volume14
Issue number1
DOIs
StatePublished - Jul 18 2013

Fingerprint

Neuroimaging
Randomized Controlled Trials
Depression
Major Depressive Disorder
Therapeutics
Emotions
Magnetic Resonance Imaging
Behavioral Genetics
Sertraline
Citalopram
Neurobiology
Task Performance and Analysis
Antidepressive Agents
Protons
Brain

Keywords

  • Antidepressant treatments
  • Biomarker
  • Imaging
  • iSPOT-D
  • Major depressive disorder

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Grieve, S. M., Korgaonkar, M. S., Etkin, A., Harris, A., Koslow, S. H., Wisniewski, S., ... Williams, L. M. (2013). Brain imaging predictors and the international study to predict optimized treatment for depression: Study protocol for a randomized controlled trial. Trials, 14(1), [224]. https://doi.org/10.1186/1745-6215-14-224

Brain imaging predictors and the international study to predict optimized treatment for depression : Study protocol for a randomized controlled trial. / Grieve, Stuart M.; Korgaonkar, Mayuresh S.; Etkin, Amit; Harris, Anthony; Koslow, Stephen H.; Wisniewski, Stephen; Schatzberg, Alan F.; Nemeroff, Charles; Gordon, Evian; Williams, Leanne M.

In: Trials, Vol. 14, No. 1, 224, 18.07.2013.

Research output: Contribution to journalArticle

Grieve, SM, Korgaonkar, MS, Etkin, A, Harris, A, Koslow, SH, Wisniewski, S, Schatzberg, AF, Nemeroff, C, Gordon, E & Williams, LM 2013, 'Brain imaging predictors and the international study to predict optimized treatment for depression: Study protocol for a randomized controlled trial', Trials, vol. 14, no. 1, 224. https://doi.org/10.1186/1745-6215-14-224
Grieve, Stuart M. ; Korgaonkar, Mayuresh S. ; Etkin, Amit ; Harris, Anthony ; Koslow, Stephen H. ; Wisniewski, Stephen ; Schatzberg, Alan F. ; Nemeroff, Charles ; Gordon, Evian ; Williams, Leanne M. / Brain imaging predictors and the international study to predict optimized treatment for depression : Study protocol for a randomized controlled trial. In: Trials. 2013 ; Vol. 14, No. 1.
@article{97bab1e7eb8f4a9e8fb1460db0ab3af3,
title = "Brain imaging predictors and the international study to predict optimized treatment for depression: Study protocol for a randomized controlled trial",
abstract = "Background: Approximately 50{\%} of patients with major depressive disorder (MDD) do not respond optimally to antidepressant treatments. Given this is a large proportion of the patient population, pretreatment tests that predict which patients will respond to which types of treatment could save time, money and patient burden. Brain imaging offers a means to identify treatment predictors that are grounded in the neurobiology of the treatment and the pathophysiology of MDD.Methods/Design: The international Study to Predict Optimized Treatment in Depression is a multi-center, parallel model, randomized clinical trial with an embedded imaging sub-study to identify such predictors. We focus on brain circuits implicated in major depressive disorder and its treatment. In the full trial, depressed participants are randomized to receive escitalopram, sertraline or venlafaxine-XR (open-label). They are assessed using standardized multiple clinical, cognitive-emotional behavioral, electroencephalographic and genetic measures at baseline and at eight weeks post-treatment. Overall, 2,016 depressed participants (18 to 65 years old) will enter the study, of whom a target of 10{\%} will be recruited into the brain imaging sub-study (approximately 67 participants in each treatment arm) and 67 controls. The imaging sub-study is conducted at the University of Sydney and at Stanford University. Structural studies include high-resolution three-dimensional T1-weighted, diffusion tensor and T2/Proton Density scans. Functional studies include standardized functional magnetic resonance imaging (MRI) with three cognitive tasks (auditory oddball, a continuous performance task, and Go-NoGo) and two emotion tasks (unmasked conscious and masked non-conscious emotion processing tasks). After eight weeks of treatment, the functional MRI is repeated with the above tasks. We will establish the methods in the first 30 patients. Then we will identify predictors in the first half (n = 102), test the findings in the second half, and then extend the analyses to the total sample.Trial registration: International Study to Predict Optimized Treatment - in Depression (iSPOT-D). ClinicalTrials.gov, NCT00693849.",
keywords = "Antidepressant treatments, Biomarker, Imaging, iSPOT-D, Major depressive disorder",
author = "Grieve, {Stuart M.} and Korgaonkar, {Mayuresh S.} and Amit Etkin and Anthony Harris and Koslow, {Stephen H.} and Stephen Wisniewski and Schatzberg, {Alan F.} and Charles Nemeroff and Evian Gordon and Williams, {Leanne M.}",
year = "2013",
month = "7",
day = "18",
doi = "10.1186/1745-6215-14-224",
language = "English",
volume = "14",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Brain imaging predictors and the international study to predict optimized treatment for depression

T2 - Study protocol for a randomized controlled trial

AU - Grieve, Stuart M.

AU - Korgaonkar, Mayuresh S.

AU - Etkin, Amit

AU - Harris, Anthony

AU - Koslow, Stephen H.

AU - Wisniewski, Stephen

AU - Schatzberg, Alan F.

AU - Nemeroff, Charles

AU - Gordon, Evian

AU - Williams, Leanne M.

PY - 2013/7/18

Y1 - 2013/7/18

N2 - Background: Approximately 50% of patients with major depressive disorder (MDD) do not respond optimally to antidepressant treatments. Given this is a large proportion of the patient population, pretreatment tests that predict which patients will respond to which types of treatment could save time, money and patient burden. Brain imaging offers a means to identify treatment predictors that are grounded in the neurobiology of the treatment and the pathophysiology of MDD.Methods/Design: The international Study to Predict Optimized Treatment in Depression is a multi-center, parallel model, randomized clinical trial with an embedded imaging sub-study to identify such predictors. We focus on brain circuits implicated in major depressive disorder and its treatment. In the full trial, depressed participants are randomized to receive escitalopram, sertraline or venlafaxine-XR (open-label). They are assessed using standardized multiple clinical, cognitive-emotional behavioral, electroencephalographic and genetic measures at baseline and at eight weeks post-treatment. Overall, 2,016 depressed participants (18 to 65 years old) will enter the study, of whom a target of 10% will be recruited into the brain imaging sub-study (approximately 67 participants in each treatment arm) and 67 controls. The imaging sub-study is conducted at the University of Sydney and at Stanford University. Structural studies include high-resolution three-dimensional T1-weighted, diffusion tensor and T2/Proton Density scans. Functional studies include standardized functional magnetic resonance imaging (MRI) with three cognitive tasks (auditory oddball, a continuous performance task, and Go-NoGo) and two emotion tasks (unmasked conscious and masked non-conscious emotion processing tasks). After eight weeks of treatment, the functional MRI is repeated with the above tasks. We will establish the methods in the first 30 patients. Then we will identify predictors in the first half (n = 102), test the findings in the second half, and then extend the analyses to the total sample.Trial registration: International Study to Predict Optimized Treatment - in Depression (iSPOT-D). ClinicalTrials.gov, NCT00693849.

AB - Background: Approximately 50% of patients with major depressive disorder (MDD) do not respond optimally to antidepressant treatments. Given this is a large proportion of the patient population, pretreatment tests that predict which patients will respond to which types of treatment could save time, money and patient burden. Brain imaging offers a means to identify treatment predictors that are grounded in the neurobiology of the treatment and the pathophysiology of MDD.Methods/Design: The international Study to Predict Optimized Treatment in Depression is a multi-center, parallel model, randomized clinical trial with an embedded imaging sub-study to identify such predictors. We focus on brain circuits implicated in major depressive disorder and its treatment. In the full trial, depressed participants are randomized to receive escitalopram, sertraline or venlafaxine-XR (open-label). They are assessed using standardized multiple clinical, cognitive-emotional behavioral, electroencephalographic and genetic measures at baseline and at eight weeks post-treatment. Overall, 2,016 depressed participants (18 to 65 years old) will enter the study, of whom a target of 10% will be recruited into the brain imaging sub-study (approximately 67 participants in each treatment arm) and 67 controls. The imaging sub-study is conducted at the University of Sydney and at Stanford University. Structural studies include high-resolution three-dimensional T1-weighted, diffusion tensor and T2/Proton Density scans. Functional studies include standardized functional magnetic resonance imaging (MRI) with three cognitive tasks (auditory oddball, a continuous performance task, and Go-NoGo) and two emotion tasks (unmasked conscious and masked non-conscious emotion processing tasks). After eight weeks of treatment, the functional MRI is repeated with the above tasks. We will establish the methods in the first 30 patients. Then we will identify predictors in the first half (n = 102), test the findings in the second half, and then extend the analyses to the total sample.Trial registration: International Study to Predict Optimized Treatment - in Depression (iSPOT-D). ClinicalTrials.gov, NCT00693849.

KW - Antidepressant treatments

KW - Biomarker

KW - Imaging

KW - iSPOT-D

KW - Major depressive disorder

UR - http://www.scopus.com/inward/record.url?scp=84880182326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880182326&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-14-224

DO - 10.1186/1745-6215-14-224

M3 - Article

C2 - 23866851

AN - SCOPUS:84880182326

VL - 14

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 224

ER -